Methylation of N6 adenosine‐related long noncoding RNA: effects on prognosis and treatment in ‘driver‐gene‐negative’ lung adenocarcinoma

Abstract

The improvement of treatment for patients with ‘driver‐gene‐negative’ lung adenocarcinoma (LUAD) remains a critical problem to be solved. We aimed to explore the role of methylation of N6 adenosine (m6A)‐related long noncoding RNA (lncRNA) in stratifying ‘driver‐gene‐negative’ LUAD risk. Patients negative for mutations in EGFR , KRAS , BRAF , HER2 , MET , ALK , RET , and ROS1 were identified as ‘driver‐gene‐negative’ cases. RNA sequencing was performed in 46 paired tumors and adjacent normal tissues from patients with ‘driver‐gene‐negative’ LUAD. Twenty‐three m6A regulators and relevant lncRNAs were identified using Pearson's correlation analysis. K‐means cluster analysis was used to stratify patients, and a prognostic nomogram was developed. The CIBERSORT and pRRophetic algorithms were employed to quantify the immune microenvironment and chemosensitivity. We identified two clusters highly consistent with the prognosis based on their unique expression profiles for 46 m6AlncRNAs. A risk model constructed from nine m6A lncRNAs could stratify patients into high‐ and low‐risk groups with promising predictive power (C‐index = 0.824), and the risk score was an independent prognostic factor. The clusters and risk models were closely related to immune characteristics and chemosensitivity. Additional pan‐cancer analysis using the nine m6AlncRNAs showed that the expression of DIO3 opposite strand upstream RNA ( DIO3OS ) is closely related to the immune/stromal score and tumor stemness in a variety of cancers. Our results show that m6AlncRNAs are a reliable prognostic tool and can aid treatment decision‐making in ‘driver‐gene‐negative’ LUAD. DIO3OS is associated with the development of various cancers and has potential clinical applications.